eMedicine from WebMD
eMedicine Home
Developed under the direction and sponsorship of Forest Laboratories, Inc. Contains promotional material.


<< InfoSite Home

Caregiver Benefits

NAMENDA:


Significantly reduces monthly care giving time25


Results of a 28-week, randomized, multicenter, double-blind, parallel-group, placebo-controlled US study. This study investigated the efficacy and safety of NAMENDA in 252 outpatients with moderate to severe AD. Patients received treatment with NAMENDA (10 mg BID) or placebo BID for 28 weeks. At week 28, 181 patients (97 NAMENDA, 84 placebo) completed the study.21


Improvements in function and behavior may reduce cost of care25

*Caregiver time includes time spent assisting in tasks such as eating, using the toilet, dressing, grooming, walking, bathing, shopping, cooking, housekeeping, laundry, transportation, taking medication, managing finances, and providing supervision.25

Next Article: Safe with Excellent Tolerability »


Important Safety Information

NAMENDA® (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer's disease. NAMENDA has been used by more than 2 million people worldwide.

NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.

See Full Prescribing Information